286 related articles for article (PubMed ID: 33929878)
1. Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations.
Labriola M; George DJ
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-5. PubMed ID: 33929878
[TBL] [Abstract][Full Text] [Related]
2. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in prostate cancer among black men: epidemiology and outcomes.
Chowdhury-Paulino IM; Ericsson C; Vince R; Spratt DE; George DJ; Mucci LA
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):397-402. PubMed ID: 34475523
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
5. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
Gong J; Kim DM; De Hoedt AM; Bhowmick N; Figlin R; Kim HL; Sandler H; Theodorescu D; Posadas E; Freedland SJ
J Clin Oncol; 2024 Jan; 42(2):228-236. PubMed ID: 37890125
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
[TBL] [Abstract][Full Text] [Related]
7. Geographic Distribution of Racial Differences in Prostate Cancer Mortality.
Fletcher SA; Marchese M; Cole AP; Mahal BA; Friedlander DF; Krimphove M; Kilbridge KL; Lipsitz SR; Nguyen PL; Choueiri TK; Kibel AS; Trinh QD
JAMA Netw Open; 2020 Mar; 3(3):e201839. PubMed ID: 32232449
[TBL] [Abstract][Full Text] [Related]
8. Racial disparities in Black men with prostate cancer: A literature review.
Lillard JW; Moses KA; Mahal BA; George DJ
Cancer; 2022 Nov; 128(21):3787-3795. PubMed ID: 36066378
[TBL] [Abstract][Full Text] [Related]
9. Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
Eggly S; Hamel LM; Heath E; Manning MA; Albrecht TL; Barton E; Wojda M; Foster T; Carducci M; Lansey D; Wang T; Abdallah R; Abrahamian N; Kim S; Senft N; Penner LA
BMC Cancer; 2017 Dec; 17(1):807. PubMed ID: 29197371
[TBL] [Abstract][Full Text] [Related]
10. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
[TBL] [Abstract][Full Text] [Related]
11. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
12. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
Lediju O; Ikuemonisan J; Salami SS; Adejoro O
J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
[TBL] [Abstract][Full Text] [Related]
13. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
14. Association of African-American ethnic background with survival in men with metastatic prostate cancer.
Thompson I; Tangen C; Tolcher A; Crawford E; Eisenberger M; Moinpour C
J Natl Cancer Inst; 2001 Feb; 93(3):219-25. PubMed ID: 11158191
[TBL] [Abstract][Full Text] [Related]
15. Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes.
Heaphy CM; Joshu CE; Barber JR; Davis C; Zarinshenas R; De Marzo AM; Lotan TL; Sfanos KS; Meeker AK; Platz EA
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):676-680. PubMed ID: 31915143
[TBL] [Abstract][Full Text] [Related]
16. Ultraviolet index and racial differences in prostate cancer incidence and mortality.
Taksler GB; Cutler DM; Giovannucci E; Smith MR; Keating NL
Cancer; 2013 Sep; 119(17):3195-203. PubMed ID: 23744754
[TBL] [Abstract][Full Text] [Related]
17. Association of race with receipt of definitive therapy for high risk prostate cancer in older men.
Patel SA; Liu Y; Mahal BA; Jani AB; Sanda MG; Royce TJ; Fischer-Valuck BW
J Geriatr Oncol; 2022 Mar; 13(2):200-206. PubMed ID: 34563484
[TBL] [Abstract][Full Text] [Related]
18. Racial Discrepancies in Overall Survival among Men Treated with
Zhao H; Howard LE; De Hoedt A; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
J Urol; 2020 Feb; 203(2):331-337. PubMed ID: 31479407
[TBL] [Abstract][Full Text] [Related]
19. Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Ward D; Essien EJ; Du XL
Cancer Control; 2009 Apr; 16(2):176-85. PubMed ID: 19337204
[TBL] [Abstract][Full Text] [Related]
20. Racial Disparity in Response to Prostate Cancer Systemic Therapies.
Bitting RL; Goodman M; George DJ
Curr Oncol Rep; 2020 Jul; 22(9):96. PubMed ID: 32700096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
